Abstract Library

#3449 Cavum neuroendocrine carcinoma

Introduction: Small cell neuroendocrine carcinoma of the head and neck is an unusual entity, especially in the cavum, given their rarity and the lack of randomized trials. The therapeutic management of these tumors is difficult. Their prognosis remains unfavourable.

Conference:

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: Small cell neuroendocrine carcinoma, Cavum,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#2864 Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,

Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,

#1726 A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)

Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pusceddu S

Authors: Femia D, Prinzi N, Vernieri C, Lo Russo G, Concas L,

Keywords: Merkel cell carcinoma, Avelumab,

#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung

Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Julien H

Authors: Kossai M, Hadoux J, Louvet E, Sullivan I, Thomas de Montpreville V,

Keywords: PD-L1, lung, neuroendocrine, immune infiltrate.,